Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 6/20 | 0.67 |
| ▸ | CA1 | P00915 | 5/20 | 0.67 |
| ▸ | CA2 | P00918 | 5/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | PDE5A | O76074 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CA3 | P07451 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280457 | 0.94 | PTGS2 (0.90) | PTGS2ALOX5CYP2C9PTGS1NPC1 | |
| SCHEMBL2602400 | 0.89 | PTGS2 (0.80) | PTGS2ALOX5CYP2C9PTGS1CA9 | |
| SCHEMBL3103964 | 0.88 | PTGS2 (0.78) | PTGS2ALOX5CYP2C9PTGS1CA9 | |
| SCHEMBL17369546 | 0.87 | ALOX5 (1.00) | PTGS2ALOX5CYP2C9PTGS1NPC1 | |
| SCHEMBL3109354 | 0.87 | PTGS2 (0.77) | PTGS2ALOX5CYP2C9PTGS1NPC1 | |
| SCHEMBL5698671 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1PDPK1 | |
| SCHEMBL5698606 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1PDPK1 | |
| SCHEMBL2615132 | 0.86 | PTGS2 (0.76) | PTGS2ALOX5CYP2C9PTGS1CA9 | |
| SCHEMBL2602398 | 0.86 | PTGS2 (0.75) | PTGS2ALOX5CYP2C9PTGS1CA9 | |
| SCHEMBL5698730 | 0.84 | CYP2C9 (0.85) | PTGS2CYP2C9PTGS1CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339184-B2 | Antibacterial compounds, compositions thereof, and methods using same | THE ROCKEFELLER UNIVERSITY (US) | 2022-05-24 | — | — | US | disclosed |
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | COCOON BIOTECH INC. | 2019-02-07 | — | — | US | disclosed |
| EP-3413889-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF | Cocoon Biotech Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139684-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF | COCOON BIOTECH INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20160200752-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | Reiley Pharmaceuticals, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-9012647-B2 | Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-04-21 | — | — | US | disclosed |
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| CN-101242875-A | Ophthalmic composition containing mucoadhesive polysaccharides capable of promoting corneal re-epithelialization | OPOCRIN SPA (IT) | 2008-08-13 | — | — | CN | disclosed |
| CN-100379727-C | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | SEARLE & CO (US) | 2008-04-09 | — | — | CN | disclosed |
| US-20080027011-A1 | Homogeneous paste and gel formulations | MERIAL LIMITED | 2008-01-31 | — | — | US | disclosed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | disclosed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | disclosed |
| US-5563165-A | PROSTAGLANDIN INHIBITOR; FDA ORANGE BOOK LISTED PATENT FOR CELEBREX | G. D. SEARL & CO. (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5521207-A | Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5516907-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200752-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | PTGS2, PTGES2, TOP2A | PTGS2 1/4885ALOX5 1074/4885CYP2C9 2620/4885 |
| US-11339184-B2 | Antibacterial compounds, compositions thereof, and methods using same | CLPP, MPO, SPOUT1 | PTGS2 1505/4885ALOX5 213/4885CYP2C9 4240/4885 |
| US-20080027011-A1 | Homogeneous paste and gel formulations | EPX, CAT, PEF1 | PTGS2 329/4885ALOX5 1571/4885CYP2C9 1064/4885 |
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | MB, PTGES, PTGS1 | PTGS2 12/4885ALOX5 276/4885CYP2C9 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.